Host Tylah Tully sat down with Optiscan CEO and Managing Director Dr Camile Farah to discuss the company’s US FDA 510(k) submission for its InForm digital pathology device, a major milestone towards potential US commercialisation.

Camile explains how InForm could transform traditional pathology through point-of-care digital imaging and outlines the next regulatory catalyst for Optiscan’s InVue surgical device.

Watch the full interview here.